Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
+0.04 (+0.05%)
: $81.21 -0.15 (-0.18%)

Merck Says U.S. FDA Accepts For Priority Review The Supplemental BLA For Vaxneuvance

Published: 12/01/2021 12:20 GMT
Merck & Co Inc (MRK) - U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s Vaxneuvance™ (pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children.
Merck & Co Inc - FDA Set a Prescription Drug User Fee Act (pdufa), Or Target Action Date, of April 1, 2022 for Vaxneuvance.